Showing 4081-4090 of 6036 results for "".
- Bausch + Lomb’s Recycling Programs Collect Over 94 Million Units of Eye Care Waste in the UShttps://modernod.com/news/bausch-lombs-recycling-programs-collect-over-94-million-units-of-eye-care-waste-in-the-us/2482541/Bausch + Lomb announced a milestone in its sustainability efforts—the company's exclusive recycling initiatives, ONE by ONE Recycling and Biotrue Eye Care Recycling programs, have successfully collected a total of 94,119,275 units of used contact lenses, eye care, and lens care material
- Ocular Therapeutix Names Namrata Saroj as Chief Business Officerhttps://modernod.com/news/ocular-therapeutix-names-namrata-saroj-as-chief-business-officer/2482536/Ocular Therapeutix announced that Namrata Saroj, OD, has joined the company as Chief Business Officer (CBO). Dr. Saroj, who has been consulting with Ocular since February 2024, brings extensive experience in clinical development and commercialization in ophthalmology. She cont
- Konan Medical USA Launches objectiveFIELD Visual Field Analyzerhttps://modernod.com/news/konan-medical-usa-launches-objectivefield-visual-field-analyzer/2482534/Konan Medical USA announced the commercial launch of its objectiveFIELD (OFA) visual field analyzer. The OFA is an objective visual field analyzer designed to detect visual field abnormalities using pupillary responses. According to Konan Medical, unlike traditional subjectiv
- AlloVir and Kalaris Announce Merger to Create Company Focused on Retina Diseasehttps://modernod.com/news/allovir-and-kalaris-therapeutics-announce-agreement-for-transformational-merger-to-create-company-focused-on-diseases-of-the-retina/2482532/AlloVir announced that it has entered into a definitive merger agreement to combine with Kalaris Therapeutics in an all-stock transaction. "On behalf of the AlloVir board, I am thrilled that we have entered into this transformational merger agreement with Kalaris,”
- Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2https://modernod.com/news/neurotech-provides-update-on-bla-for-nt-501-as-a-treatment-for-macular-telangiectasia-type-2/2482531/Neurotech Pharmaceuticals announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date by 3 months to allow time required for the FDA to review additional data provided by the company in response to recent requests from the FDA. Originally set for December 17
- Astellas Withdraws European Application for Avacincaptad Pegol for GAhttps://modernod.com/news/astellas-withdraws-european-application-for-investigational-geographic-atrophy-treatment/2482517/Astellas Pharma announced it is withdrawing its marketing authorization application for avacincaptad pegol (ACP) from the European Medicines Agency (EMA). ACP, an investigational intravitreal treatment designed to inhibit the complement C5 protein, was developed for geographic atrophy (
- EyePoint Pharmaceuticals Doses First Patient in Phase 3 LUGANO Trial for Wet AMD Therapy Duravyuhttps://modernod.com/news/eyepoint-pharmaceuticals-doses-first-patient-in-phase-3-lugano-trial-for-wet-amd-therapy-duravyu/2482512/EyePoint Pharmaceuticals announced dosing of the first patient in its phase 3 LUGANO clinical trial of Duravyu. This investigational sustained delivery therapy, formerly known as EYP-1901, aims to treat wet age-related macular degeneration (AMD) using a patent-protected formulation of vorolanib,
- Science Corporation: PRIMA Clinical Trials Show Restoration of "Form Vision"https://modernod.com/news/science-corporation-announces-breakthrough-in-retinal-implant-technology-prima-clinical-trials-show-restoration-of-form-vision/2482509/Science Corporation, a developer in brain-computer interface (BCI) technology, has announced preliminary results from clinical trials of its PRIMA retina implant. This technology has demonstrated the ability to restore what the company is calling 'form vision' in patients suffer
- Ocuphire Acquires Gene Therapy Company Opus Geneticshttps://modernod.com/news/ocuphire-acquires-gene-therapy-company-opus-genetics/2482508/Ocuphire Pharma announced an all-stock acquisition of Opus Genetics, a clinical-stage gene therapy company specializing in inherited retinal diseases (IRDs). As part of the deal, the combined company will be renamed Opus Genetics, effective October 23, 2024, and will begin trading under the
- Cathleen McCabe, MD, Appointed Strategic Medical Advisor at Bausch + Lombhttps://modernod.com/news/cathleen-mccabe-md-appointed-strategic-medical-advisor-at-bausch-lomb/2482507/Bausch + Lomb has appointed Cathleen McCabe, MD, as Strategic Medical Advisor. According to B+L, in this new consultancy role, Dr. McCabe will contribute her expertise to Bausch + Lomb’s product portfolio expansion and collaborate with the research and development team to drive in